EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:8212 - pimozide
| Formula | C28H29F2N3O |
| Net Charge | 0 |
| Average Mass | 461.556 |
| Monoisotopic Mass | 461.22787 |
| SMILES | O=c1nc2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1 |
| InChI | InChI=1S/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34) |
| InChIKey | YVUQSNJEYSNKRX-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | H1-receptor antagonist H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. dopaminergic antagonist A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. |
| Applications: | H1-receptor antagonist H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. anxiolytic drug Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. antidepressant Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. dopaminergic antagonist A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. first generation antipsychotic Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased. antidyskinesia agent Any compound which can be used to treat or alleviate the symptoms of dyskinesia. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| pimozide (CHEBI:8212) has role antidepressant (CHEBI:35469) |
| pimozide (CHEBI:8212) has role antidyskinesia agent (CHEBI:66956) |
| pimozide (CHEBI:8212) has role anxiolytic drug (CHEBI:35474) |
| pimozide (CHEBI:8212) has role dopaminergic antagonist (CHEBI:48561) |
| pimozide (CHEBI:8212) has role first generation antipsychotic (CHEBI:65190) |
| pimozide (CHEBI:8212) has role H1-receptor antagonist (CHEBI:37955) |
| pimozide (CHEBI:8212) has role serotonergic antagonist (CHEBI:48279) |
| pimozide (CHEBI:8212) is a benzimidazoles (CHEBI:22715) |
| pimozide (CHEBI:8212) is a heteroarylpiperidine (CHEBI:48585) |
| pimozide (CHEBI:8212) is a organofluorine compound (CHEBI:37143) |
| IUPAC Name |
|---|
| 1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one |
| INNs | Source |
|---|---|
| pimozida | ChemIDplus |
| pimozide | WHO MedNet |
| pimozide | ChemIDplus |
| pimozidum | ChemIDplus |
| Synonyms | Source |
|---|---|
| MCN-JR-6238 | ChEMBL |
| NSC-170984 | ChEMBL |
| pimozide | IUPHAR |
| Pimozide | KEGG COMPOUND |
| R 623 | ChEMBL |
| R-623 | ChEMBL |
| Brand Names | Source |
|---|---|
| Halomonth | DrugBank |
| Neoperidole | DrugBank |
| Opiran | DrugBank |
| Orap | KEGG DRUG |
| Citations |
|---|